Skip to main content

Cell Therapeutics'


shares rose Friday after the company announced plans to close a trial on its drug Xyotax for the treatment of lung cancer. The company plans to focus on a new trial specifically involving women with normal estrogen levels, a subgroup of patients that has already demonstrated the greatest survival advantage when treated with the drug. The stock rose 1.7% to $1.85.



announced plans to acquire privately held biopharmaceuticals company


for approximately $454 million in cash. Shares dipped 5 cents to $52.50.


( ENCY) shares gained 8.3% to $6.56 after the company said it received regulatory approval to resume a hypertension drug trial that was halted over safety concerns early this year.



said treatments with its anabolic drug ostarine led to a gain in lean body mass and improved patients' ability to function, based on trial results reported after the close of trading Thursday. However, the company says it will conduct an additional midstage efficacy trial on the drug, slated to begin in the summer of 2007. Shares sank 4.5% to $15.99.

Shares of



Scroll to Continue

TheStreet Recommends

sank 6.5% to $6.50 Friday after the company announced the resignation of its CEO, Bradford Goodwin, citing personal reasons. The company's board of directors appointed its chairman, John Walker, as the interim CEO. Goodwin plans to work through year-end to help facilitate the transition, the company says.

Among Friday's actively trading winners,



was up 1.6% $70.27,



rose 1.7% to $56.33,



added 1% to $121.64, and

The Medicines Company


gained 12.8% to $34.60.

Among losers,

Omrix Biopharmaceuticals

( OMRI) slipped 4.9% to $32.31,

Cubist Pharmaceuticals


fell 7.2% to $18.97,


( NTY) lost 2.7% to $36.70,

Adams Respiratory Therapeutics

( ARXT) sank 2.4% to $39.56, and



shed 1.5% to $5.90.